Bladder Cancer Awareness Day 🎗️
Hematuria should never be ignored. Early evaluation saves lives.
At Urology Group Aalst, we offer 20+ years of expertise in minimally invasive bladder cancer care, with tailored treatments for every patient.
https://t.co/6Vj3MZU1rJ
🔥 Tremendous week for Urology Group Aalst at AZORG 🔥
🥇First Belgian tele-proctoring RARP by Dr. Geert De Naeyer & Dr. Frederiek D'Hondt
🥇 First AI-supported RAPN by Prof. Dr. Alex Mottrie & Dr. Ir. Pieter De Backer
https://t.co/ST7Mb9o4mx
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: https://t.co/6M3xhml0ou
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy https://t.co/3uNr9TUukQ
One month ago, Edward Lambert successfully defended his PhD thesis, focusing on optimizing outcomes for patients with localized or metastatic prostate cancer. This achievement reflects UGA's ongoing commitment to advancing knowledge and improving patient care.
Proud of our two colleagues Prof. Dr. Alex Mottrie and Dr. Ir. Pieter De Backer for their achievements as pioneers in AI driven surgery. The future of surgery is being built here! 🦾🩺
https://t.co/fOHieMeFUG
#DataDriven#ORSI#AI#Innovation#DeTijd#AalstUrologyGroup
Dr. Ir. Pieter De Backer has joined the Aalst Urology Group as the 13th member of the team. As a urologist and engineer, he is considered an international expert in innovation and AI-driven surgical support. He will mainly focus on surgical innovation and robot-assisted surgery.
Congrats 🎊 @EdwLambert it was a huge step forward and your work on #prostate#cancer has really been appreciated we will remember it not only for the quality of your data but also for the weather conditions ❄️
Earlier this week, I successfully defended my PhD, marking the conclusion of a long and rigorous doctoral journey. Grateful to my promotors Charles Van Praet and Nicolaas Lumen, and to all jury members, for their guidance and critical insights. Looking ahead to new challenges!
Great day of sharing experience and insights on bladder cancer surgery. Honoured to be part of the expert panel discussion on advancing intracorporeal robotic neobladder surgery in Perugia 🇮🇹 🤖
Special thanks to Prof. @RoccoPapaliaUro@AalstOlv@alexmottrie
🛜🥇🤖First teleproctoring case in Europe: Robot-assisted radical prostatectomy tele-surgery with two sugeons 600 kms apart as a live-case for the German Society for Robot-Assisted Urology #DRUS congress 🇩🇪.
@gdnaeyer@alexmottrie@MicroPort#Toumai
https://t.co/KMSm9NqRXJ
pCR rate of 57% after NA EV+P in Cis ineligble BCa patients. How will we select those who can preserve their bladder?
Exciting data presented by @cvulsteke at #ESMO25#bladdercancer
KN905
Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25
✅Improved PFS & OS
✅High path CR rates (57%)
✅No delay in surgery
✅Expected toxicity in this frail population
New SOC
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery
Very happy and honoured to have shared our insights from @AalstOlv on robot-assisted cystectomy with neobladder at this wonderfull first RARC - neobladder masterclass. Hope to see you again next year!
Let's break the silence, challenge the stigma, and prioritize men's health this month and beyond. Together, we can make a difference.
Laten we het zwijgen doorbreken, stigma wegwerken & de gezondheid van mannen deze maand en daarna prioriteit geven. Samen maken we het verschil💙